FDA approval establishes setmelanotide as the first labeled option for acquired hypothalamic obesity, addressing a population ...

First and only FDA-approved therapy for the treatment of acquired hypothalamic obesity, a rare disease characterized by accelerated and sustained weight gain caused by hypothalamic injury or dysfuncti ...

The FDA has approved an expanded indication for setmelanotide to treat children and adults with acquired hypothalamic obesity, Rhythm Pharmaceuticals announced. Setmelanotide (Imcivree, Rhythm ...

PANTHERx® Rare Pharmacy, the trusted leader and innovator in patient access and support services for personalized rare disease care, announced that it was selected by Rhythm Pharmaceuticals, Inc.

The U.S. Food and Drug Administration (FDA) on Thursday approved an expanded indication for Rhythm Pharmaceuticals Inc.’s RYTM Imcivree (setmelanotide) to treat acquired hypothalamic obesity (HO). The ...

Rhythm Pharmaceuticals (NASDAQ:RYTM) shares rose 11% Friday morning following FDA approval of IMCIVREE (setmelanotide) for patients with acquired hypothalamic obesity. The approval marks the first and ...

Rhythm Pharma has secured the first approval in the US for a drug to treat hypothalamic obesity, a rare condition in which damage to or a malfunction of the hypothalamus leads to excessive weight gain ...

Rhythm Pharmaceuticals (RYTM) stock gains as FDA OKs a label expansion for the company's lead asset, Imcivree, to treat acquired hypothalamic obesity. Read more here.

Future treatment resistance to focal epilepsy therapy was significantly more likely in individuals who reported suicidal ...

First and only FDA-approved therapy for the treatment of acquired hypothalamic obesity, a rare disease characterized by accelerated and sustained weight gain caused by hypothalamic injury or ...

Rhythm Pharmaceuticals stock ultimately closed down Friday, though the FDA signed off on its drug, Imcivree, for a genetic ...